Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Insys Therapeutics, Inc." (INSY) Report Updated: Nov 30, 2015 | Print This Page

Get more stock ratings by Louis Navellier

"Insys Therapeutics, Inc." (INSY)

Rating: Strong Buy Volatility: Moderate
Total Grade: A Industry: Biotechnology
Competitors: REGN, ZIOP, TRVN, EGRX

Stock Analysis

Rating: Monthly View

November December January February March April May June July August September October

Rating: Weekly View

This Week: A down no change
Last Week: A same no change
Two Weeks Ago: A up no change
service keys

"Insys Therapeutics, Inc."© quotemedia

Company Profile

INSYS Therapeutics, Inc., a development stage company, develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray, a single-use product for the treatment of breakthrough cancer pain; and Dronabinol SG capsule, an ANDA approved product and Dronabinol Oral Solution, which completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting, and appetite stimulation in AIDS patients. It also develops proprietary cancer therapeutics comprising LEP-ETU, a NeoLipid liposomal, which is in Phase II clinical development stage to enhance efficacy and reduce paclitaxel-related side effects. The company was founded in 2002 and is based in Phoenix, Arizona.

Recent News: "Insys Therapeutics, Inc."